Copy number signatures in cervical samples enable early detection of high-grade

serous ovarian carcinoma

Laura Martin de la Fuente[1,#], Srinivas Veerla[1,#], Minerva X. Li[1], Guyuan Tang[1,^], Anna Ebbesson[1],

Laura Mannarino[2,3], Lara Paracchini[2,3], Sergio Marchini[3], Maurizio D'Incalci[2,3], Anna Måsbäck[4],

Susanne Malander[1], Päivi Kannisto[5], Ingrid Hedenfalk[1,*]

[1]Division of Oncology, Department of Clinical Sciences Lund and Lund University Cancer Centre,

Lund University and Skåne University Hospital Comprehensive Cancer Centre, Lund, Sweden

[2]Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

[3]Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

[4]Department of Surgical Pathology, Division of Laboratory Medicine, Skåne University Hospital,

Lund, Sweden

[5]Department of Obstetrics and Gynaecology Lund, Skåne University Hospital, Lund University,

Lund, Sweden

[#]These authors contributed equally to this work

[^]Current affiliation: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,

Stockholm, Sweden

*Corresponding author: Ingrid.Hedenfalk@med.lu.se

ABSTRACT

Background: Ovarian cancer is often diagnosed in advanced stages, resulting in poor outcomes. There is an unmet need for a sensitive and specific screening tool for early-stage detection of ovarian cancer. **Methods:** Recognizing that high-grade serous ovarian carcinoma (HGSC) is driven by copy number alterations (CNAs) and that tumor DNA can be detected in cervical samples, we analyzed CNAs from shallow whole genome sequencing of 212 cervical samples from 128 women with/without HGSC, including 29 germline *BRCA1/2* mutation carriers. Using a machine-learning classifier, we developed **H**igh-grade serous ovarian cancer **C**ervical copy number **sig**nature (HCsig), a predictor for HGSC detection. **Results:** HGSC-derived CNAs were detectable with HCsig in cervical samples collected several years before diagnosis. Importantly, HCsig correctly identified HGSC in 79% of archival cervical samples, including 91% stage I-II (0-27 months pre-diagnosis), and 77% stage III-IV (0-65 months pre-diagnosis). Among patients with HGSC who had multiple pre-diagnostic samples collected during the pre-symptomatic phase, 85% had at least one HCpositive cervical sample before surgery (up to 65 months before diagnosis). Detection rates were 90% and 76% for *BRCA1/2*-mutated and wildtype HGSC, respectively. Validation in 172 independent samples (0-98 months pre-diagnosis) showed 76% sensitivity and 94% specificity (AUC=0.83), including high sensitivity for early-stage cancers. **Conclusions:** We show that applying the HCsig classifier to cervical samples, including from non-symptomatic women several years before diagnosis, holds promise for early-stage detection and secondary prevention of HGSC. Moreover, it may serve as a screening tool to aid decision-making regarding timing of risk-reducing surgery in high-risk populations.

KEYWORDS

High-grade serous ovarian cancer, whole genome sequencing, liquid biopsy, copy number alteration, early detection

BACKGROUND

Almost two-thirds of women diagnosed with ovarian cancer die from their disease (1). One of the

main reasons for the high mortality rate is the lack of effective screening methods leading to

diagnosis in advanced stages. As women detected with localized disease have a survival rate >90%,

considerable efforts are being invested in developing effective screening tools for early detection.

The majority of high-grade serous tubo-ovarian carcinomas (HGSC) are derived from precursor

lesions arising from epithelial cells in the fimbriated end of the fallopian tubes (2). Pre-cancerous

lesions, so-called serous tubal intraepithelial carcinomas (STICs) harbor clonal *TP53* mutations and

display a histological appearance resembling HGSC (3) (4). Dysplastic cells harboring mutant *TP53*

(p53 signatures) are believed to precede the STIC lesions (5) (6). These findings provide evidence for

the possibility of finding tumor-driving mutations in asymptomatic women with early-stage HGSC

(7). To this end, Kinde *et al.* showed that somatic mutations in DNA shed from ovarian cancers could

be detected in standard liquid-based Pap test specimens collected at the time of diagnosis by

massively parallel sequencing (8). More recently, we and others have reported the detection of

tumor-specific *TP53* mutations in archival liquid-based cervical cytology samples obtained from

asymptomatic women up to several years prior to the HGSC diagnosis using ultra-sensitive methods

(9) (10). However, it has recently been shown that very low-frequency, cancer-like, age-related *TP53*

mutations are found in healthy women, revealing the challenge of using mutations in *TP53* for the

early detection of ovarian cancer (11) (12). Hence, while sensitivity has been the main constraint in

previous studies, specificity has emerged as the major challenge for early detection using ultra-

sensitive sequencing approaches.

HGSC is a prototypical tumor characterized by genomic instability, where mutational processes

acting on cancer genomes drive copy number alterations (CNAs) that can be readily investigated by

whole genome sequencing (WGS) (13). In fact, evolutionary analyses have reported that aneuploidy

and genomic instability, in addition to *TP53* mutations, can occur as early in HGSC progression as in

the STIC lesions (14). To address the possibility of detecting the earliest steps in the evolution of

HGSC using an unbiased approach, we therefore applied low-pass/shallow WGS (sWGS) to assess

the consequence of the earliest known molecular event in the development of HGSC, mutations in

TP53, leading to genomic instability. In this study, we interrogated genome-wide CNAs in a

discovery cohort of 309 samples, including 212 cervical samples collected at surgery and archival

samples from routine screening for cervical cancer taken up to 94 months prior to surgery from

HGSC patients, *BRCA1/2* mutation carriers undergoing risk-reducing salpingo-oophorectomy

(RRSO) and women with benign gynecological conditions. We explored genomic landscapes in the

cervical samples using copy number signatures derived from HGSC (15) as well as pan-cancer copy

number signatures for chromosomal instability (16) (17). To derive novel copy number signatures

more fitting for low DNA-abundance cervical samples we used the unsupervised, machine learning-

based clustering method Systematic Random forest Integration with Qualitative threshold (SRIQ)

(18) to develop the **H**igh-grade serous ovarian cancer **C**ervical copy number **sig**nature (HCsig)

classifier. A prediction model was constructed based on centroids for HCsig, which was tested and

validated in an independent cohort of 172 samples from HGSC and healthy women (**Figure 1**). Our

findings demonstrate the feasibility of applying sWGS to standard cervical samples for simple,

minimally invasive, and accurate early detection of HGSC, with the potential for downstaging and

improved survival. As a screening tool for risk assessment in high-risk populations, *e.g.* women with

germline mutations in *BRCA1/2*, HCsig may support clinical decision-making regarding the timing

of RRSO.

Figure 1. Overview of patients, samples and workflow for HCsig. Liquid- and slide-based cervical samples from

women with HGSC, *BRCA1* and *BRCA2* mutation carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) and

women with benign gynecological conditions were used for sWGS. Cervical samples were from 0-94 months before

surgery. The random forest machine learning-based clustering method SRIQ was applied to define HGSC-derived copy

number signatures, HCsig 1-5. Validation was performed using an independent cohort of women with HGSC and healthy

controls (external cohort), as well as normal tissues, tumors and blood/plasma from the discovery cohort (internal cohort).

Created using BioRender.com.

METHODS

Study design

The discovery cohort in the present study included 128 patients and 309 samples: 173 samples from

58 women diagnosed with HGSC, 82 samples from 48 women diagnosed with benign gynecological

conditions and 54 samples from 22 *BRCA1/2* mutation carriers who underwent RRSO. Clinical

information and sample types by patient group are presented in **Table 1**.

Two in-house cohorts contributed to the discovery cohort; one prospective cohort where diagnostic

cervical samples were collected from 187 women who underwent RRSO or had surgery due to

adnexal masses at the Gynecological Department in Lund, Skåne University Hospital, Sweden

(2015-2017) (9) and one cohort where 59 patients with HGSC or RRSO surgery (2017-2020), with

accessible archival cervical samples, were retrospectively identified. To be eligible for this study, the

availability of archival samples was also required from the patients in the first cohort. A flowchart of

the inclusion and exclusion of patients is shown in **Figure S1**. The study was approved by the Ethics

Committee at Lund University, Sweden.

Table 1. Patient and sample information

		HGSC	RRSO	Benign	Total
Patients (n)		**58**	**22**	**48**	**128**
Age	Range (years)	43-77	36-73	23-86	
	Median (years)	64	45	66	
BRCA1/2 Mutant (n)		10*	22	0	**32**
	Wildtype (n)	42	0	0	**42**
	Not tested (n)	6	0	48	**54**
Stage	Advanced (FIGO III and IV) (n)	47	N/A	N/A	
	Localized (FIGO I and II) (n)	11	N/A	N/A	
CA-125	Range (U/mL)	7.4-11,666†	†	4.1-1,207†	
	Median (U/mL)	925	N/A	35	
Samples (n)		**173**	**54**	**82**	**309**
Cervical samples (n)		**117**	**40**	**55**	**212**
	Diagnostic (n)	31	17	55	103
	Archival (n)	86	23	0	109
Additional samples (n)		**56**	**14**	**27**	**97**
	Tumor tissue (n)	18	N/A	N/A	18
	Normal tissue‡ (n)	9	7	13	29
	Blood (n)	18	4	7	29
	Plasma (n)	11	3	7	21

117   HGSC, high-grade serous ovarian cancer; RRSO, risk-reducing salpingo-oophorectomy

118   *, n=6 germline *BRCA1* mutations, 1 germline *BRCA2* mutation, 3 somatic *BRCA1* mutations

119   †, missing CA-125 values: n=2 HGSC, 22 RRSO, 12 benign

120   ‡, endometrium, ovary, uterus

121   N/A, not applicable

Cervical samples

Archival cervical samples from cervical cancer screening were obtained from the Pathology

Department at Skåne University Hospital, Sweden, while fresh-frozen tissue, blood, and plasma

samples were available from the regional biobank for gynecological conditions in the southern

Swedish healthcare region. Liquid-based cervical cytology samples were preserved in either

DNAgard® (Sigma-Aldrich), ThinPrep® solution (Hologic) or SurePath® solution (BD

Biosciences). Diagnostic samples were collected at surgery, and archival samples were from any

time before surgery (range: 0 to 94 months).

In total, we analyzed 117 cervical samples from the HGSC group: 31 diagnostic cervical samples

(from 19 patients), and 86 archival samples (from 52 patients). For the RRSO group, we analyzed 40

cervical samples: 17 samples were collected at surgery (from 12 patients), and 23 were archival

(from 14 patients). Fifty-five diagnostic cervical samples were from women with benign

gynecological conditions (48 women). Twenty-five patients (20 HGSC and five RRSO) had samples

available from multiple time points. In addition, blood, plasma, tumor and normal tissues were also

collected, for a total of 309 samples from 128 patients (**Table S1**).

Sample processing and library preparation

The cover glass or film was removed from cervical cytology slides using xylene or acetone,

respectively, and DNA was extracted with the Maxwell RSC DNA FFPE kit (Promega). Liquid-

based cervical samples were extracted with the QIAamp DNA Micro kit (Qiagen). For the additional

samples, DNA was extracted using the AllPrep DNA/RNA Mini kit (fresh-frozen tissue) or QIAmp

DNA Blood Midi kit (blood and plasma).

DNA concentrations were measured by Qubit fluorometric assays and quality-checked by Illumina

TruSeq FFPE Library Prep QC Kit (Illumina). The QIAseq FX DNA library prep kit (Qiagen) was

used for library preparation according to the manufacturer's protocol. Briefly, sequencing libraries

were prepared from 1-10 ng DNA with 4-12 cycles of amplification depending on the DNA input.

qPCR with EvaGreen DNA-binding dye was used to monitor library enrichment. Low pass/shallow

whole genome sequencing (sWGS) was performed on the NovaSeq 6000 platform (Illumina) at the

Center for Translational Genomics (CTG) in Lund, Sweden. The target sequencing depth was >1X

for all sample types, except blood and plasma, which were sequenced at 0.5X. Approximately 15%

of the extracted cervical samples were not sequenced due to poor DNA quality and/or quantity.

Data analysis workflow

A data analysis workflow was assembled to extract copy number features from all samples. We

calculated similarities with previously published cancer-derived copy number signatures and

generated novel copy number signatures from HGSC in cervical samples using sWGS data.

Demultiplexed FASTQ files from paired-end sWGS data were used as input. The workflow contains

copy number analysis to generate relative copy number profiles and solutions for cellularity and

ploidy, as well as the manually curated segmentation bin sizes for each sample. Absolute copy

number profiles were generated and used to explore HGSC-derived copy number signatures

(CNsignatures) (15), pan-cancer chromosomal instability copy number signatures (CIN signatures)

(16), and allele-specific copy number signatures (panConusig) (17). For the construction of the

HGSC-specific cervical copy number prediction model HCsig, we used the absolute copy number

profiles of the cervical samples from patients with and without HGSC, performed unsupervised

SRIQ clustering (18) to generate copy number-based signatures and subsequently a prediction model,

which was then tested and validated using an independent dataset from Paracchini *et al.* (19).

Absolute copy number analysis

Raw sequencing data were demultiplexed using Illumina's bcl2fastq software to generate FASTQ

files, which were subsequently aligned to the reference genome (hg38) using BWA (v0.7.17-r1188).

The alignment files were processed with Samtools (v1.13) to convert SAM to BAM format, followed

by duplicate marking using PicardTools (v3.3.0), and GATK software (v4.1) was applied for base

quality score recalibration (BQSR).

Relative copy number profiles were generated using a modified version of QDNAseq (20). Custom

bin annotations for the hg38 reference genome were created to optimize the analysis for a 100bp

paired-end sequencing setup, following the package's recommended workflow. A new control

dataset, comprising 58 human genomes from the 1000 Genomes Project Phase 3, was incorporated to

enhance analytical accuracy.

The segmented relative copy number profiles, derived under manually optimized bin sizes for the

309 samples, were processed using the Rascal R package. Rascal employs the ACE (Absolute Copy-

number Estimation) method to scale relative copy numbers to absolute values. To refine the results,

we applied an additional model adjustment using mutant allele frequencies (MAFs) for *TP53*,

previously quantified via ddPCR (IBSAFE®, Saga Diagnostics) in three patients (9).

Integration with published copy number signatures

The outputs generated by Rascal were utilized to derive sample-by-component matrices for HGSC-

specific copy number signatures (15) and pan-cancer chromosomal instability (CIN) signatures (16).

We performed a cosine similarity analysis to identify signatures with the most similar patterns in our

dataset. This compared the sample-by-component matrices with the corresponding signature-by-

component definition matrices, resulting in sample-by-signature matrices containing cosine similarity

values.

For cases with matched blood samples, we applied panConusig (17), which leverages allele-specific

copy number profiles. Prior to calculating these profiles, we used a modified workflow of Battenberg

v2.2.9 on the BAM files to generate haplotype-phased data. The workflow was adapted to include

only the initial steps: counting the major and minor allele frequencies and determining phased states.

The haplotype-phased allele frequency data were subsequently processed with the shallow-coverage

version of ASCAT (ASCAT.sc v0.1) to calculate allele-specific copy number profiles.

Construction of HGSC-derived copy number signatures (HCsig) using cervical samples

Absolute copy number profiles in cervical samples from women with HGSC were used to extract

genome-wide copy number features. These features included segment sizes (segsize), breakpoint

counts per 10Mb (bp10MB), lengths of oscillating copy number segment chains (osCN), copy

number change points (changepoint), segment copy numbers (copynumber), and breakpoint counts

per chromosome arm (bpchrarm). Each feature was further decomposed into distinct components

using mixture modeling, as described in (15), resulting in 36 unique components. These components

formed the basis of a sample-by-component matrix. This matrix was then used as input for the SRIQ

algorithm (18), an unsupervised clustering approach that integrates principles from the Random

Forest machine learning classifier, quality thresholding, and k-nearest neighbor clustering. The aim

of the SRIQ method is to delineate a core cluster of samples or components sharing common patterns

without the need for *a priori* knowledge of the data or a predetermined number of clusters (K). As a

result of this analysis, distinct clusters were successfully identified. For each resulting cluster, a

centroid was computed. The centroids represent the mean vector (or average components profile) of

all samples within the cluster, effectively capturing the dominant alteration pattern or signature

characteristic of that cluster and were used to create the HCsig classifier.

Validation of the centroid-based prediction tool HCsig in independent data

The HCsig signature profiles were used to develop and validate a prediction model for identifying

HGSC in an independent cohort comprising 172 samples. This cohort included 44 biopsy samples,

and 128 cervical samples collected from presymptomatic women, with 62 samples from individuals

diagnosed with HGSC and 66 from healthy controls (19). The downloaded BAM files, which were

processed using genome reference hg38, were run through our analysis pipeline to produce a sample-

by-component matrix. Each sample was compared to the HCsig centroids using Spearman

correlation. Samples were then annotated with the HCsig signature showing the highest Spearman

correlation value. Samples with close similarity to two centroids, one of which being HCsig1

(delta<0.05 between HCsig1 and any other HCsig) were considered as HCpositive. A custom Java-

based tool (see Code Availability section) was developed for this analysis. The model's performance

was evaluated using a receiver operating characteristic (ROC) curve, with the area under the curve

(AUC) providing an overall measure of predictive accuracy. Additionally, confusion matrix metrics,

including sensitivity, specificity, and accuracy, were calculated to assess the model's ability to

classify samples accurately as originating from HGSC patients or healthy controls. All performance

analyses, including calculations and visualizations, were conducted using Python's scikit-learn

package.

Fraction of Genome Altered (FGA) analysis

236   To calculate FGA, we used segmented data derived from the sWGS analysis. Genomic segments

237   were classified as altered if their log2 ratio exceeded an absolute threshold (set at ±0.2). Next, we

238   summed the genomic length of all altered segments. Finally, FGA was computed by dividing the

239   total length of altered regions by the total autosomal genome size (excluding sex chromosomes). For

240   classification purposes, samples with an FGA of 20% or higher were classified as positive.

Statistical analyses

Chi-square tests were used for categorical variables. P<0.05 was considered statistically significant.

Confidence intervals (95% CI) were calculated using the Normal Approximation method. Cosine

similarity was used to quantify the closeness between different signature exposure profiles. Spearman

correlation was used to assign HCsig signatures to samples in the validation cohort.

RESULTS

sWGS and cancer-derived copy number signatures in cervical samples, tumors and normal

tissues

The discovery cohort consisted of cervical samples (slide- and liquid-based, collected at diagnosis,

and up to 8 years before diagnosis), tumors, blood/plasma and normal tissues from a previously

published prospective cohort (9), and a retrospective cohort (total n=58 HGSC, 22 RRSO and 48

with benign gynecological conditions). The patient cohorts and sample types are shown in **Table 1**.

Information on *BRCA1* and *BRCA2* (henceforth *BRCA1/2*) mutation status, FIGO stage and CA-125

levels was retrieved from patient records. The majority of the HGSC patients were diagnosed with

advanced-stage disease (47/58, 81%). We applied sWGS to all samples, aiming at a coverage of

approximately 1X (range 0.4-2.2X). Although the DNA quality from slides was poorer than the

liquid-based cervical samples, the results of the library preparation and sequencing were satisfactory.

The average number of mapped reads was 49.2×10^6, 25.4×10^6, 19.8×10^6, 41.7×10^6, 40.6×10^6,

57.9×10^6 for tumor, blood, plasma, normal tissues, slide-based, and liquid-based cervical samples,

respectively (range: 27.2×10^6-63.4×10^6, 18.1×10^6-41.8×10^6, 16.5×10^6-24.8×10^6, 32.1×10^6-64.1×10^6,

12.7×10^6-55.3×10^6, 34.0×10^6-105.0×10^6) (**Figure S2**). Various fixed bin sizes were explored based

on sequencing quality using QDNASeq (20), with a final selection of 50kb for all sample types. The

generation of relative and absolute copy numbers, and the assessment of copy number signatures,

was performed as outlined in the Methods section.

Signature similarity exposure profiles from three previously published collections of cancer-derived

copy number signatures (15) (16) (17) were evaluated to identify copy number patterns across sample

types, including cervical samples (diagnostic samples from the time of surgery and archival samples

collected during routine screening for cervical cancer), tumor and normal tissue, blood and plasma

from women with HGSC, women at high risk of developing HGSC due to germline *BRCA1/2*

mutations and women with benign gynecological conditions (**Table S2**). The HGSC-derived CN

signatures (15) more readily captured CNAs in cervical samples from HGSC patients in our cohort

compared to the pan-cancer signatures (**Figure S3, Table S1**). Overall, HGSC and pan-cancer

signatures defined by a high number of breakpoints, short to medium-sized, clustered and oscillating

copy number changes, proposed to be caused by impaired homologous recombination, replication

stress and/or chromothripsis, were commonly observed in tumors and cervical samples from patients

with HGSC. In addition, the allele-specific panConusig signatures also captured LOH events in both

tumors and a subset of cervical samples.

Collation and exploration of HGSC-derived copy number signatures using cervical samples

The previously reported copy number signatures were derived from advanced-stage cancers (15);

therefore, we hypothesized that they may lack the sensitivity required for capturing the early stages

of HGSC in cervical samples. With the aim of developing a screening test for the early detection of

HGSC using cervical samples, we decided to use the cervical samples in our discovery cohort to

generate copy number signatures indicative of HGSC based on the six fundamental copy number

features previously reported as hallmarks of genomic aberrations (15), and found in both HGSC

tumor tissue and cervical samples in our cohort.

Cervical samples from the HGSC group (n=117) and the benign and RRSO groups (n=55 and 40,

respectively) were included in the analysis. To generate HCsig, a copy number-based classifier for

HGSC using cervical samples, we applied the unsupervised, random forest machine learning-based

clustering method SRIQ (18) to discover clusters of samples in our data and to identify the copy

number features defining these clusters. SRIQ identified five discrete copy number clusters

(signatures), with the majority of the HGSC cervical samples being enriched for HCsig1. The

heatmap in **Figure 2A** displays the five clusters and their defining features in each sample, and the

bar plot in **Figure 2B** shows the weights of the defining components in the signatures, denoted

HCsig 1-5.

The majority (67/117, 57%) of the HGSC cervical samples clustered together and exhibited

enrichment for HCsig1, defined by highly variable segment sizes, oscillating copy number events,

one to two breakpoints per chromosome arm, breaks evenly distributed across the genome, single

copy number change points and copy number two. Notably, HCsig1 shared many features with the

HGSG-derived CN signatures s3, s6 and s7 related to homologous recombination deficiency (HRD)

and failure of cell cycle control (15), and was identified as a descriptor for HGSC in the HGSC

cervical samples in our cohort.

Figure 2. Copy number features underlying the HCsig classifier in cervical samples. (A). SRIQ-based clustering and

heatmap of cervical samples from patients with HGSC (n=117), benign gynecological disease (n=55) and who had RRSO

(n=40). Samples are clustered on the x-axis, with the HCsig clusters 1-5 and patient groups shown above. The copy number

features are shown on the y-axis. **(B).** Bar plot displaying the distributions and weights of the defining copy number

components for HCsig 1-5.

HCsig 2-5 demonstrated few defining copy number features and limited differences; these signatures

were mainly defined by large segment sizes and few breakpoints. The majority of the cervical

samples from women with benign conditions and from women who had undergone RRSO were

enriched for HCsig 2-5, suggesting that large segment sizes and the occurrence of few breakpoints

are not tumor-specific features. Taken together, samples enriched for HCsig1 (*i.e.* if HCsig1 was the

most highly enriched signature, or, alternatively, if HCsig1 was the second-most enriched signature

with a delta <0.05 compared to the highest signature, see Methods) were considered as HCpositive.

We next examined whether our sWGS approach could be used to capture HGSC in archival cervical

samples, mirroring the pre-diagnostic/pre-symptomatic setting. The HCsig clusters were converted

into centroids and used to perform a binary centroid-based prediction analysis: HCpositive or

HCnegative. In total, 46/58 (79%) women with HGSC had at least one positive cervical sample

before surgery. Liquid and slide-based cervical samples showed similar distributions of HCsig 1-5

and similar fractions of HCpositive and HCnegative samples, indicating limited impact of sample

processing (**Figure S4**). Importantly, 91% (10/11) of women with stage I-II HGSC had at least one

positive cervical sample before surgery (range: 0-27 months), while 77% (36/47) of women with

advanced stage disease (stage III-IV) had at least one positive cervical sample before surgery (range:

0-65 months). Notably, for women with *BRCA1/2*-mutated tumors (germline or somatic), 90% (9/10)

were detectable in at least one pre-diagnostic cervical sample (range: 0-54 months), compared to

76% (32/42) of the *BRCA1/2* wildtype tumors (range: 0-51 months). Among healthy women in the

benign group, 9/48 (19%) had a false positive cervical sample, while 11/22 (50%) *BRCA1/2* germline

mutation carriers who had an RRSO, one of whom displayed STICs according to the pathology

reports, had an HCsig positive sample (**Figure 3**). There were no differences in exposure to HCsig 1-

5 between cervical samples from *BRCA1/2*-mutated HGSC and those from women with sporadic

HGSC (**Figure S5**). To further explore the distribution and origin of the features identified in the

HCsig signatures, we investigated the exposures across different sample types using cosine

similarity, clearly demonstrating enrichment of the HCpositive class in the majority of tumor tissue

samples (15/18, 83%), validating the HGSC origin of HCsig1. Only 3/18 (16%) blood and 4/11

(36%) plasma samples from HGSC patients were HCpositive, indicating lower sensitivity in

peripheral samples compared to cervical samples (**Figure 3**).

Figure 3. Circular annotation plot summarizing clinical, pathological and molecular features and HCsig across all

samples (n = 309), including cervical (68.6%) and non-cervical (31.4%) samples. The outer ring represents the disease

group, showing the distribution of HGSC (56.0%), RRSO (17.5%), and benign (26.5%) cases. The next ring indicates

sample type, including cervical (68.6%), tumor (5.8%), normal tissues (9.4%), plasma (6.8%), and blood (9.4%) samples.

BRCA1/2 mutation status is represented in the following ring, with mutated (25.9%), wild-type (31.4%), and not tested

(42.7%) cases. The fourth ring depicts HCsig, derived from our genomic classifier, showing HCpositive (41.1%) and

HCnegative (58.9%) cases. The fifth ring encodes FIGO stage at HGSC diagnosis spanning early to advanced disease: IA

(2.3%), IC (1.0%), IIA (3.6%), IIB (0.3%), IIIA (1.6%), IIIB (2.3%), IIIC (34.0%), IVA (1.3%), IVB (9.4%), and NA

(44.3%). Note: Excluding samples from the benign and RRSO groups, the distribution is: IA (4.0%), IC (1.7%), IIA (6.4%),

IIB (0.6%), IIIA (2.9%), IIIB (4.0%), IIIC (60.7%), IVA (2.3%), IVB (16.8%), NA (0.6%). The innermost ring displays

patient age using a bar plot and color gradient from light blue to dark blue, with age groups distributed as follows: 20–30

(0.3%), 30–40 (1.3%), 40–50 (23.6%), 50–60 (15.9%), 60–70 (33.0%), 70–80 (24.6%), and 80–90 (1.3%) years,

respectively.

When including all sample types from all patient groups in the analysis, the sensitivity of the HCsig

classifier was 86%, the specificity 79% and the accuracy 82%. The normal samples (blood, plasma

and normal tissues) displayed similar exposures to all HCsig signatures, *i.e.* no enrichment of tumor-

like features. There were no indications in the pathology reports specifying the presence of invasive

features in tissues from women with an HCpositive sample from the benign or RRSO groups.

However, the fallopian tube tissue from one of the women who had undergone an RRSO was found

to display a STIC lesion. Taken together, the most distinguishing features captured in HCsig1

(HCpositive) in cervical samples from HGSC patients were also more prevalent in tumor tissue

compared to normal tissues.

Modelling pre-symptomatic detection: analysis of HCsig in longitudinal cervical samples from

HGSC patients

To explore the ability of the HCsig classifier to capture copy number features from HGSC in cervical

samples collected during routine gynecological examination of pre-symptomatic women and who

were later diagnosed with HGSC, we applied the HCsig classifier to archival cervical samples to

simulate the pre-symptomatic setting. Women later diagnosed with HGSC, who had ≥2 cervical

samples taken at different timepoints were included in the analysis (n=20 patients) and samples were

ordered according to the time of sampling in relation to the time of diagnosis (range: 0-94 months).

The HCsig classification of cervical samples from women diagnosed with HGSC sorted by time is

shown in **Figure 4**. Enrichment for the HCpositive class was observed in both diagnostic and

archival cervical samples from women with HGSC. Seventeen of 20 patients with HGSC (85%) had

at least one HCpositive cervical sample before surgery (up to 65 months before diagnosis).

Enrichment for the HCpositive class in archival samples obtained up to >5 years before diagnosis

supports the notion that copy number features captured from sWGS data may enable early detection

of HGSC in pre-symptomatic women. In summary, these findings show that complex CNAs

resembling those observed in HGSC and captured using HCsig can be detected in archival cervical

samples obtained from asymptomatic women up to several months, and even years, prior to the onset

of symptoms and subsequent diagnosis.

Figure 4. HCsig classification in longitudinal cervical samples from women with HGSC. The dot plot shows the

classification of cervical samples from women with HGSC and ≥2 cervical samples available. The x-axis shows the time

in months before diagnosis (right to left). Filled circles represent HCpositive samples and open circles represent HCnegative

samples. FIGO stage at diagnosis of HGSC is indicated for each patient on the right y-axis.

Validation of the HCsig classification model for HGSC using samples from an independent dataset

Finally, to examine the diagnostic potential of our classification model, we performed a validation

using an independent dataset with a comparable number of samples and patients, including archival

cervical samples from women with HGSC and healthy women. The time from the collection of

cervical samples to the time of HGSC diagnosis ranged from 0 months to 13.6 years (19). sWGS data

(1-5X) from 172 samples were preprocessed and analyzed as for the discovery cohort. To account for

differences in sample quality and expected CNA resolution, normal cytology samples from healthy

donors were processed at a coarser resolution, using a 500 kb bin size. This approach reduced noise

and improved signal stability, which is appropriate given the lower DNA yield and complexity of

normal samples. In contrast, samples from the HGSC group (tumors and cervical cytology samples)

were analyzed at a finer resolution (50 kb bin size) to capture both focal and broad CNAs more

accurately. The SRIQ-derived HCsig clusters were converted into centroids and used to perform a

binary centroid-based prediction analysis (HGSC or healthy donors). Cross-tabulation was

performed, showing the correct classification of 81/106 HGSC and 62/66 non-HGSC samples.

Among women with HGSC and at least one cervical sample, 43/61 (70%) women had at least one

HCpositive cervical sample (up to 98 months before diagnosis). In all, only four false positive and 25

false negative samples were found, yielding a specificity of 94% (95% CI: 0.90, 0.98) and sensitivity

of 76% (95% CI: 0.70, 0.83). A receiver operating characteristic curve yielded an accuracy of

AUC=0.83 (95% CI: 0.78, 0.89) (**Figure 5**). Notably, HCsig detected a majority of the early-stage

HGSC cases (5/7) in the cervical samples from the external cohort.

For benchmarking purposes, and to gauge the performance of HCsig in relation to an established

metric, Fraction of Genome Altered (FGA) (21), we computed FGA values for all samples across

both cohorts, showing inferior sensitivity, specificity and accuracy compared to HCsig (**Table S3**).

Figure 5. Validation of HCsig in the independent cohort. The receiver-operating characteristics curve (ROC) shows the
sensitivity (x-axis) and specificity (y-axis) of HCsig in the independent cohort from Paracchini *et al.* (19) with healthy
women and women with HGSC.

DISCUSSION

In the present study we have demonstrated that the early detection of genomically aberrant HGSC-

derived DNA in cervical samples collected from asymptomatic women is feasible. Increased early

detection rates may enable earlier-stage diagnosis and hence improve survival rates for women with

the most common type of ovarian cancer, HGSC. A screening tool for early detection of HGSC is an

urgent unmet medical need and is required to be both highly sensitive and specific. Based on the

premise that HGSC-derived cells and DNA can be shed into the cervix due to the anatomical

connection via the uterine cavity and given evidence of genomic instability patterns in early HGSC

development (7) , we developed HCsig, a model leveraging copy number signatures from sWGS data

for the early detection of HGSC in conventional cervical samples. While ultra-deep sequencing

approaches have illustrated the possibility of highly sensitive detection of cancer-derived mutant

TP53 (11) (22), the occurrence of somatic clonal evolution linked to ageing limits its utility as a

diagnostic test.

We show that sWGS combined with machine learning to characterize genomic features prototypical

of HGSC and readily captured in cervical samples is both sensitive and specific, despite the low

abundance of HGSC-derived DNA in the cervical samples. This approach provides a quantitative and

qualitative measure of CNAs, presenting an improvement over previous purely quantitative measures

like FGA (21) and gene-centric methods (8) (23) (24). Sampling in close proximity to the tumor

mass contributes to the accuracy of this approach, supported by the higher fraction of true positive

cervical samples vs. plasma samples from HGSC patients.

While retrospective in nature, the access to archival cervical samples allowed for an unbiased

investigation of CNAs in non-symptomatic women up to several years before their HGSC diagnosis.

The inability to correctly classify a subset of cervical samples from women with HGSC may be due

to the closeness in time to surgery, involving multiple samplings during work-up, resulting in inferior

sample quality or insufficient tumor-derived DNA. Another possible explanation may be blockage of

the fallopian tubes in advanced-stage disease. Importantly, the performance of our model was

validated in an independent cohort with high accuracy, suggesting that it is generalizable across

populations and laboratories.

HGSC is characterized by a low frequency of recurrent oncogenic mutations, few recurrent CNAs

and highly complex genomic profiles, which pose challenges for screening, diagnosis and

classification of the disease. Novel approaches to early detection have focused on identifying the

ubiquitous *TP53* mutations (9) (10) or a small panel of cancer-related genes (25) (24) in plasma or in

samples of cervical or uterine origin. The main constraint of these mutation-based screening studies

has been the lack of sensitivity, while specificity has recently emerged as the key challenge due to

ultra-sensitive methods capturing clonal evolution of cancer-like age-related *TP53* mutations in

healthy women and normal tissues (11). However, unlike mutations, CNAs are rarely present in

normal tissues and may thus present a robust foundation for creating a test able to distinguish early

cancer from benign or normal tissue. A quantitative analysis of genomic instability was recently

proposed for early detection of ovarian cancer in cervical samples collected up to several years

before diagnosis, with promising results (19). In the present study, we used an unsupervised

approach, including mixture modelling and cosine similarities to extract both quantitative and

qualitative genomic features known to occur in HGSC (15) for each cervical sample to generate a

prediction model based on the distinct copy number features of HGSC. Importantly, the method is

tumor mutation agnostic, able to capture early-stage disease, relatively inexpensive, and requires

only small amounts of tumor-derived DNA. We provide proof-of-concept that CNAs found in

archival cervical samples can be used as a biomarker to distinguish between HGSC and benign

gynecological conditions, up to several years before the onset of symptoms and diagnosis. Of note,

some women in the study underwent frequent sampling due to suspected cervical cell atypia, but

these samples were generally called as HCnegative by the classifier, hence not confounding the

results. Importantly, both advanced-stage and localized HGSC were detectable using our classifier,

supporting the sensitivity and specificity of HCsig and the reported early genomic evolution of

HGSC from STIC lesions (7). The detection of early-stage cancers, involving growth only on the

ovaries and/or fallopian tubes, supports the robustness of the classifier and provides a promising

approach for early detection with the possibility of increasing curability and reducing mortality. This

supports the notion that sampling in close proximity to the tumor holds superior sensitivity over *e.g.*

plasma and reflects the tubal origin of HGSC. Enrichment of copy number signatures indicative of

mutational processes described in HGSC (15) and other epithelial cancers (16) (17), including HRD

and tandem duplications support the HGSC-derived origin in the cervical samples in our study. In

line with our findings, using a combination of whole-genome cell-free DNA (cfDNA) fragmentome

and protein biomarker (CA-125 and HE4) analysis, Medina *et al.* recently reported a high accuracy

for the detection of stage I-IV HGSC (26). Exploring our HCsig classifier in combination with

fragmentomes in cervical samples and conventional protein biomarkers may improve the

performance further.

A strength of our study was the inclusion of women with germline *BRCA1/2* mutations at high risk of

developing HGSC, who underwent RRSO and hence a thorough pathology review. While no

invasive cancers were detected, STIC lesions were noted for one of 13 women. Of note, 13/22 (59%)

positive cervical samples from non-HGSC patients ('false positives') were from *BRCA1/2* mutation

carriers, suggesting that *BRCA1/2* heterozygous cells may instigate carcinogenesis in the fallopian

tubes due to potential haploinsufficiency. This possibility is supported by reports of *BRCA1*

haploinsufficiency causing genomic instability in mammary epithelial cells (27, 28). There was a

trend toward lower exposure to HCsig1 and HCsig3 in the HCsig positive samples from the RRSO

group compared to the HGSC group with *BRCA1/2* mutations, potentially also supporting a

haploinsufficient state in at-risk germline *BRCA1/2* mutant fallopian tube tissue. Reports suggest a

prevalence of around 5-6% STICs in asymptomatic *BRCA1/2* mutation carriers (29) and the life-time

risk of developing ovarian cancer for germline *BRCA1* and *BRCA2* mutation carriers is 44% and 17%

without RRSO, respectively (30). An interval of several years from the occurrence of STIC lesions to

the development of HGSC has been proposed (7, 29), indicating a potential window of opportunity

for capturing loss of genomic integrity caused by heterozygous inactivation of *BRCA1* or *BRCA2*

using HCsig. Furthermore, complex somatic CNAs can be found in early (stage I) ovarian cancers

(31), corroborating HCsig as a tool for early diagnosis. Further exploration of the individual

components of HCsig 1-5 in a larger cohort of asymptomatic women with germline *BRCA1/2*

mutations until the time of RRSO in connection with detailed genomic and pathology review at the

single cell level will allow for refinement of HCsig in the RRSO setting and to establish a cut-off for

distinguishing between the *BRCA1/2* heterozygous state and complete loss of function. A recent

report showed that *TP53* mutation burden in cervical cytology samples increased with age in

BRCA1/2 germline mutation carriers with HGSC (22), leading to greater genomic instability. This

finding further supports the potential of risk assessment based on cumulative genomic instability

using *e.g.* HCsig to aid in decision-making regarding the timing of RRSO for high-risk women.

CONCLUSIONS

To summarize, we have shown that HGSC-derived copy number signatures can be captured with

high sensitivity and specificity in cervical samples obtained from cervical cancer screening

programs, including in samples collected up to several years before diagnosis, from women later

diagnosed with HGSC, importantly including early-stage cancers. The results were validated in an

independent, external cohort, strengthening the findings further and supporting the robustness and

generalizability of the method. Our findings indicate that early-stage detection is possible in

asymptomatic women, opening the possibility for the development of a copy number-based tool for

early diagnosis. HCsig may be applied in a screening setting for early detection in high-risk

individuals, and as a diagnostic tool in symptomatic women. Further characterization of the

signatures and a large, prospective study should pinpoint which components to include in a

diagnostic tool for early detection and increased survival.

ABBREVIATIONS

ACE: Absolute Copy-number Estimation

ASCAT: Allele-Specific Copy Number Analysis of Tumors

BRCA1/2: Breast and Ovarian Cancer Susceptibility Protein 1/2

CA-125: Cancer Antigen 125 (Mucin 16)

cfDNA: cell-free DNA

CNA: Copy Number Alteration

FGA: Fraction of Genome Altered

FIGO: International Federation of Gynecology and Obstetrics

HCsig: High-grade serous ovarian cancer Cervical copy number signature

HE4: Human Epididymis Protein 4

HGSC: High-Grade Serous Cancer

HRD: Homologous Recombination Deficiency

RRSO: Risk-Reducing Salpingo-Oophorectomy

STIC: Serous Tubal Intraepithelial Carcinoma

sWGS: shallow Whole Genome Sequencing

TP53: Tumor Protein P53

DECLARATIONS

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Ethics Committee at Lund University, Sweden (2014/717), with

written informed consent for the prospective part of the discovery cohort and waiving the

requirement for informed consent for the retrospective part of the discovery cohort.

CONSENT FOR PUBLICATION

All authors approved the final manuscript.

AVAILABILITY OF DATA AND MATERIALS

Data Availability

The data presented in this paper contain sensitive human information (whole genome sequencing)

that cannot be shared openly. Processed data files and metadata necessary to reproduce the key

findings are available at Mendeley under doi: 10.17632/d45hf6nxfv.2, in accordance with data-

sharing and ethical guidelines.

Code Availability

All analyses were performed using open-source software such as R, and Java programming language.

The pipeline and other source codes used in this study can be found at:

https://github.com/IngridHLab/HCsig, https://github.com/IngridHLab/CentriodClassification,

https://github.com/sunnyveerla/SRIQ.

COMPETING INTERESTS

The authors declare that they have no competing interests.

FUNDING

The Swedish Cancer Society grants 21 1684 Pj and 24 3839 Pj (IH)

The Sjöberg Foundation grant 2023-639 (IH)

The Berta Kamprad Foundation grant FBKS-2023-36 (IH)

The Cancer and Allergy Foundation grants 10381, 10672 and 11002 (IH)

The King Gustaf V Jubilee Foundation grant 197011 (IH)

Governmental funding of clinical research within the national health services (ALF) grant 40615

(IH)

Fondazione Alessandra Bono and AIRC grants IG 2024 ID30972 and ID30381 (MD, SM)

578   AUTHORS' CONTRIBUTIONS

Conceptualization: LMF, PK, IH

Resources: LMF, LP, LM, SM, MD, AM, SM, PK, IH

Data curation: LMF, SV, ML, AE, IH

Methodology: SV, ML, GT, AE, IH

Investigation: LMF, SV, AE, IH

Visualization: SV, AE

Funding acquisition: SM, MD, IH

Project administration: IH

Supervision: SV, IH

Writing – original draft: IH

Writing – review & editing: all authors

591   ACKNOWLEDGMENTS

The authors wish to thank all patients who participated in the study, RCC South for providing

infrastructure for the collection and biobanking of samples, SciLifeLab/Center for Translational

Genomics (CTG) Lund University for sequencing services. We thank J-M Jönsson for critical review

and feedback on the manuscript.

AUTHORS' INFORMATION

Laura Martin de la Fuente and Srinivas Veerla contributed equally to this work.

Corresponding author: Ingrid Hedenfalk, Ingrid.Hedenfalk@med.lu.se

SUPPLEMENTARY INFORMATION

602   Supplementary Figures S1–S5 and Tables S1-S3

REFERENCES

1.   Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer

statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185

countries. CA Cancer J Clin. 2024;74(3):229-63.

2.   Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal

fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstetr Gynecol.

2007;19(1):3-9.

3.   Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial

carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg

Pathol. 2007;31(2):161-9.

4.   Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate

precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26-35.

5.   Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al.

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing

ovarian cancer. J Pathol. 2001;195(4):451-6.

6.   Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings

of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol.

2006;100(1):58-64.

7.   Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade serous

ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.

8.   Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M, et al. Evaluation of DNA

from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med.

2013;5(167):167ra4.

9.   Arildsen NS, Martin de la Fuente L, Masback A, Malander S, Forslund O, Kannisto P, et al.

Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer

patients using an ultra-sensitive ddPCR method. Sci Rep. 2019;9(1):15506.

10.   Paracchini L, Pesenti C, Delle Marchette M, Beltrame L, Bianchi T, Grassi T, et al. Detection

of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade

Serous Epithelial Ovarian Cancer Diagnosis. JAMA Netw Open. 2020;3(7):e207566.

11.   Salk JJ, Loubet-Senear K, Maritschnegg E, Valentine CC, Williams LN, Higgins JE, et al.

Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in

Normal Tissue over a Century of Human Lifespan. Cell Rep. 2019;28(1):132-44 e3.

12.   Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, et al. Ultra-

deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations

in noncancerous tissues. Proc Natl Acad Sci U S A. 2016;113(21):6005-10.

13.   Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The

repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94-101.

14.   Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, et al. Genomics

of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial

Metastasis to the Fallopian Tube. Cancer Discov. 2016;6(12):1342-51.

15.   Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, et al. Copy

number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018;50(9):1262-70.

16.   Drews RM, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, et al. A pan-cancer

compendium of chromosomal instability. Nature. 2022;606(7916):976-83.

17.   Steele CD, Abbasi A, Islam SMA, Bowes AL, Khandekar A, Haase K, et al. Signatures of

copy number alterations in human cancer. Nature. 2022;606(7916):984-91.

18.   Karlstrom J, Aine M, Staaf J, Veerla S. SRIQ clustering: A fusion of Random Forest, QT

clustering, and KNN concepts. Comput Struct Biotechnol J. 2022;20:1567-79.

19.   Paracchini L, Mannarino L, Romualdi C, Zadro R, Beltrame L, Fuso Nerini I, et al. Genomic

instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of

high-grade serous ovarian cancer. Sci Transl Med. 2023;15(725):eadi2556.

20.   Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA

copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing

with identification and exclusion of problematic regions in the genome assembly. Genome Res.

2014;24(12):2022-32.

21.   Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer

genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer

Discov. 2012;2(5):401-4.

22.   Ghezelayagh TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, Latorre-Esteves E, Tee

XR, et al. TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with

and without ovarian cancer and BRCA1 or BRCA2 germline mutations. Oncogene.

2024;43(31):2421-30.

23.   Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, Vergote I, et al.

Lavage of the Uterine Cavity for Molecular Detection of Mullerian Duct Carcinomas: A Proof-of-

Concept Study. J Clin Oncol. 2015;33(36):4293-300.

24.   Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, et al. Evaluation of liquid from the

Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci

Transl Med. 2018;10(433).

25.   Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-

stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403).

26.   Medina JE, Annapragada AV, Lof P, Short S, Bartolomucci AL, Mathios D, et al. Early

detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer

Discov. 2024;15(1):105-18.

27.   Sedic M, Skibinski A, Brown N, Gallardo M, Mulligan P, Martinez P, et al.

Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature

senescence. Nat Commun. 2015;6:7505.

28.   Martins FC, De S, Almendro V, Gonen M, Park SY, Blum JL, et al. Evolutionary Pathways

in BRCA1-Associated Breast Tumors. Cancer Discov. 2012;2(6):503-11.

29.   Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, et al. Outcome of unexpected

adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line

BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014;132(2):280-6.

30.   Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation

Carriers. JAMA. 2017;317(23):2402-16.

31.   Pesenti C, Beltrame L, Velle A, Fruscio R, Jaconi M, Borella F, et al. Copy number

alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with

prognosis. Eur J Cancer. 2022;171:85-95.